Oncology Central

ASH 2018 round-up: practice-changing data for leukemia subtype and more

Yet again the 60th American Society of Hematology (ASH) Annual Meeting and Exposition (December 1–4, 2018; CA, USA) has unearthed a wealth of hematologic research. Here, we compile the key headlines and ground-breaking research from the meeting. Highlights include:

CASSINI data: DOACs could reduce blood clots for cancer patients

One of the key late-breaking abstracts from the meeting was the CASSINI study. This trial demonstrated that taking Direct Oral Anticoagulants (DOACs) can reduce the risk of harmful blood clots in patients undergoing cancer treatments without substantially increasing the risk of bleeding problems.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.